FIDALTO Trademark

Trademark Overview


On Monday, December 16, 2019, a trademark application was filed for FIDALTO with the United States Patent and Trademark Office. The USPTO has given the FIDALTO trademark a serial number of 88728509. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 17, 2023. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The FIDALTO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
fidalto

General Information


Serial Number88728509
Word MarkFIDALTO
Filing DateMonday, December 16, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 17, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 21, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, July 17, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 17, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, January 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 4, 2023SOU EXTENSION 5 GRANTED
Wednesday, December 14, 2022SOU EXTENSION 5 FILED
Wednesday, January 4, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 14, 2022TEAS EXTENSION RECEIVED
Friday, June 17, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 15, 2022SOU EXTENSION 4 GRANTED
Wednesday, June 15, 2022SOU EXTENSION 4 FILED
Wednesday, June 15, 2022TEAS EXTENSION RECEIVED
Wednesday, December 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 13, 2021SOU EXTENSION 3 GRANTED
Monday, December 13, 2021SOU EXTENSION 3 FILED
Monday, December 13, 2021TEAS EXTENSION RECEIVED
Thursday, June 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 15, 2021SOU EXTENSION 2 GRANTED
Tuesday, June 15, 2021SOU EXTENSION 2 FILED
Tuesday, June 15, 2021TEAS EXTENSION RECEIVED
Friday, December 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 9, 2020SOU EXTENSION 1 GRANTED
Wednesday, December 9, 2020SOU EXTENSION 1 FILED
Wednesday, December 9, 2020TEAS EXTENSION RECEIVED
Tuesday, June 16, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 21, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 21, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 1, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 16, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 16, 2020ASSIGNED TO EXAMINER
Thursday, December 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 19, 2019NEW APPLICATION ENTERED